International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 4, Page 51-58.
https://doi.org/10.5281/zenodo.19473566

Review Article

Antibiotic Resistance: A Global Public Health Challenge – A Review

Sanjana Ostwal*, Padma Pawar, Minakshi Londhe, Ashwini Shewale, Shital Boraste

PDEA'S Shankarrao Ursal College of Pharmacy (Diploma), Kharadi Pune, Maharashtra, India

Antibiotic resistance (AR) has emerged as one of the most serious global public health threats of the 21st century. The increasing prevalence of resistant bacterial strains has reduced the effectiveness of commonly used antibiotics, leading to prolonged illness, higher healthcare costs, and increased mortality. Antibiotic resistance arises due to genetic mutations and the acquisition of resistance genes, often accelerated by the irrational use of antibiotics in human medicine, veterinary practice, and agriculture. This review discusses the mechanisms of antibiotic resistance, major resistant pathogens, contributing factors, clinical and economic impacts, and current strategies to combat antibiotic resistance.

Keywords: Antibiotic resistance, multidrug resistance, antimicrobial stewardship, superbugs, public health.

INTRODUCTION

The discovery of antibiotics marked a turning point in medical history by significantly reducing deaths from bacterial infections. However, the widespread and often inappropriate use of antibiotics has accelerated the development of antibiotic resistance. Antibiotic resistance occurs when bacteria adapt to survive exposure to antimicrobial agents, rendering standard treatments ineffective. The World Health Organization (WHO) has identified antibiotic resistance as one of the top ten global public health threats. The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria poses a serious challenge to healthcare systems worldwide, particularly in low- and middle-income countries.

2. Mechanisms of Antibiotic Resistance

Bacteria employ various mechanisms to resist the action of antibiotics, either through intrinsic properties or acquired genetic changes. Antibiotic resistance arises when bacteria develop the ability to survive exposure to antimicrobial agents that are designed to inhibit or kill them. These resistance mechanisms may be intrinsic or acquired through genetic mutations and horizontal gene transfer involving plasmids, transposons, and integrons. The major mechanisms by which bacteria resist antibiotics include enzymatic inactivation, target site modification, reduced drug permeability, and active efflux of antibiotics. Often, multiple mechanisms operate simultaneously, leading to multidrug resistance.

2.1 Enzymatic Drug Inactivation

Enzymatic inactivation is one of the most prevalent and clinically significant mechanisms of antibiotic resistance. In this mechanism, bacteria produce specific enzymes that chemically modify or degrade antibiotic molecules, thereby neutralizing their antimicrobial activity before the drug can reach its target site. These resistance enzymes are often encoded by genes located on plasmids, transposons, or integrons, facilitating their rapid dissemination among bacterial populations through horizontal gene transfer. The most extensively studied enzymes involved in antibiotic inactivation are β-lactamases, which hydrolyze the β-lactam ring of penicillins,

cephalosporins, monobactams, and carbapenems. Based on their structural and functional characteristics, β-lactamases are classified into several groups, including extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, and carbapenemases such as KPC, NDM, and OXA-type enzymes. The emergence of carbapenem-resistant Enterobacteriaceae has significantly limited treatment options and poses a major threat to public health. Apart from β-lactam antibiotics, resistance through enzymatic modification also affects other antibiotic classes. Aminoglycoside-modifying enzymes, including acetyltransferases, phosphotransferases, and nucleotidyltransferases, alter aminoglycoside molecules, reducing their ability to bind to bacterial ribosomal targets. Similarly, chloramphenicol acetyltransferase inactivates chloramphenicol by acetylation, preventing its interaction with the 50S ribosomal subunit. Enzymatic inactivation not only compromises antibiotic efficacy but also accelerates the spread of multidrug resistance, as resistance genes are frequently co-localized with other antimicrobial resistance determinants. Understanding this mechanism is crucial for the development of enzyme inhibitors, such as β-lactamase inhibitors, and for guiding rational antibiotic therapy in clinical practice. Certain bacteria produce enzymes that chemically modify or degrade antibiotics. β-lactamase enzymes, for example, hydrolyze β-lactam antibiotics such as penicillins and cephalosporins, leading to treatment failure.

2.2 Target Site Modification

Target site modification is a major mechanism of antibiotic resistance in which bacteria alter the molecular structures that antibiotics normally bind to, thereby reducing or completely eliminating drug affinity. These alterations may occur due to spontaneous chromosomal mutations or the acquisition of resistance genes through horizontal gene transfer. As a result, antibiotics fail to inhibit essential bacterial processes such as cell wall synthesis, protein synthesis, or nucleic acid replication. One of the most well-known examples of target site modification is observed in **methicillin-resistant *Staphylococcus aureus* (MRSA)**. Resistance in MRSA is mediated by the *mecA* gene, which encodes an altered penicillin-binding protein (PBP2a) with low affinity for β-lactam antibiotics. This allows cell wall synthesis to continue even in the presence of high antibiotic concentrations. Modification of ribosomal target sites is another important resistance mechanism. **Macrolide, lincosamide, and streptogramin (MLS) resistance** occurs due to methylation of the 23S rRNA by enzymes encoded by *erm* genes. This methylation reduces antibiotic binding to the 50S ribosomal subunit, leading to cross-resistance among multiple antibiotic classes. Similarly, mutations in ribosomal proteins or rRNA can confer resistance to aminoglycosides and tetracyclines. Alterations in enzymes involved in nucleic acid synthesis also contribute to resistance. **Fluoroquinolone resistance** commonly arises from point mutations in genes encoding DNA gyrase (*gyrA*) and topoisomerase IV (*parC*), decreasing the binding of fluoroquinolones to these essential enzymes. Additionally, resistance to **rifampicin** is associated with mutations in the *rpoB* gene, which encodes the β-subunit of RNA polymerase. Target site modification often results in high-level and clinically significant resistance, limiting therapeutic options. This mechanism highlights the importance of molecular surveillance and the development of novel antibiotics capable of binding to modified targets or acting through alternative pathways.

2.3 Reduced Drug Permeability

Changes in membrane permeability, particularly in Gram-negative bacteria, limit antibiotic entry into the cell. Loss or alteration of porin proteins contributes to resistance against several antimicrobial classes. Reduced drug permeability is an important mechanism of antibiotic resistance, particularly in **Gram-negative bacteria**, where structural changes in the outer membrane limit antibiotic entry into the bacterial cell. Antibiotics must cross the bacterial cell envelope to reach their intracellular targets; any alteration that restricts this entry significantly reduces drug effectiveness. In Gram-negative organisms, hydrophilic antibiotics such as β-lactams, fluoroquinolones, and tetracyclines enter the cell primarily through **porin channels** located in the outer membrane. Resistance develops when bacteria decrease the expression of these porins, alter their size or charge, or completely lose specific porin proteins.

For example, loss or modification of OmpF and OmpC porins in *Escherichia coli* and OprD porin in *Pseudomonas aeruginosa* has been associated with resistance to β-lactams and carbapenems. Structural modifications in the bacterial cell wall and membrane composition also contribute to decreased permeability. Changes in lipopolysaccharide (LPS) content can reduce membrane fluidity, limiting antibiotic penetration. In *Mycobacterium tuberculosis*, the presence of a thick, lipid-rich cell wall containing mycolic acids acts as a natural permeability barrier, contributing to intrinsic resistance against several antibiotics. Reduced drug permeability often acts synergistically with other resistance mechanisms, such as enzymatic inactivation or efflux pump overexpression, leading to **multidrug resistance**. This combined effect poses a significant challenge in clinical therapy, as increasing antibiotic doses may not overcome the permeability barrier and can result in toxicity. Understanding permeability-related resistance is critical for the design of antibiotics with improved membrane penetration and for developing adjuvant therapies that enhance drug uptake.

2.4 Efflux Pump Overexpression

Efflux pumps actively expel antibiotics from bacterial cells, lowering intracellular drug concentrations. This mechanism is commonly associated with resistance to tetracyclines, fluoroquinolones, and macrolides. Efflux pump overexpression is a significant mechanism of antibiotic resistance in which bacteria actively expel antimicrobial agents from the cell, thereby reducing intracellular drug concentrations below therapeutic levels. Unlike enzymatic inactivation or target site modification, efflux-mediated resistance does not chemically alter the antibiotic but prevents it from accumulating at its site of action. This mechanism is widespread among both Gram-positive and Gram-negative bacteria and contributes substantially to multidrug resistance. Efflux pumps are membrane-associated transport proteins that utilize energy derived from ATP hydrolysis or proton motive force to transport antibiotics out of the cell. Based on their structure and energy source, efflux pumps are classified into several families, including the **ATP-binding cassette (ABC)**, **major facilitator superfamily (MFS)**, **resistance–nodulation–division (RND)**, **small multidrug resistance (SMR)**, and **multidrug and toxic compound extrusion (MATE)** families. Among these, RND-type efflux pumps are particularly important in Gram-negative bacteria. In *Pseudomonas aeruginosa*, overexpression of the MexAB-OprM efflux system confers resistance to multiple antibiotic classes, including β-lactams, fluoroquinolones, tetracyclines, and chloramphenicol. Similarly, the AcrAB-TolC efflux pump in *Escherichia coli* plays a central role in resistance to fluoroquinolones and macrolides. In Gram-positive bacteria, MFS-type efflux pumps such as NorA in *Staphylococcus aureus* contribute to fluoroquinolone resistance. Efflux pump overexpression is often regulated by mutations in global or local regulatory genes, leading to constitutive pump activity. Moreover, efflux mechanisms frequently act in combination with reduced drug permeability and enzymatic degradation, resulting in high-level multidrug resistance and treatment failure. Targeting efflux pumps through the development of **efflux pump inhibitors (EPIs)** represents a promising strategy to restore antibiotic efficacy. However, clinical application of EPIs remains limited due to toxicity and pharmacokinetic challenges. Continued research into efflux regulation and inhibition is essential for overcoming this resistance mechanism.

3. Major Antibiotic-Resistant Pathogens

The rapid emergence and global dissemination of antibiotic-resistant pathogens have become a critical challenge in clinical practice. Several bacterial species have developed resistance to multiple classes of antibiotics, significantly limiting therapeutic options and increasing morbidity and mortality. These pathogens are commonly associated with both community-acquired and hospital-acquired infections**.**

Staphylococcus aureus

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most prevalent resistant pathogens worldwide. MRSA strains exhibit resistance to most β-lactam antibiotics due to altered penicillin-binding proteins and are frequently associated with skin and soft tissue infections, pneumonia, and bloodstream infections.

Enterobacteriaceae

Members of the Enterobacteriaceae family, particularly *Escherichia coli* and *Klebsiella pneumoniae*, have developed resistance through the production of extended-spectrum β-lactamases (ESBLs) and carbapenemases. These organisms are major causes of urinary tract infections, sepsis, and intra-abdominal infections. Carbapenem-resistant Enterobacteriaceae (CRE) are associated with high mortality rates.

Pseudomonas aeruginosa

Pseudomonas aeruginosa is an opportunistic pathogen with intrinsic resistance to many antibiotics and a remarkable ability to acquire additional resistance mechanisms. Multidrug-resistant *P. aeruginosa* commonly causes infections in immunocompromised patients, particularly ventilator-associated pneumonia and burn wound infections.

Acinetobacter baumannii

Acinetobacter baumannii has emerged as a significant cause of hospital-acquired infections, especially in intensive care units. Multidrug-resistant and extensively drug-resistant strains show resistance to β-lactams, aminoglycosides, and fluoroquinolones, often leaving limited treatment options such as colistin.

Enterococcus species

Vancomycin-resistant enterococci (VRE), particularly *Enterococcus faecium*, pose a serious threat in healthcare settings. Resistance to glycopeptides complicates the treatment of bloodstream, urinary tract, and surgical site infections**.**

Mycobacterium tuberculosis

Drug-resistant tuberculosis remains a major global health concern. Multidrug-resistant tuberculosis (MDR-TB) is resistant to isoniazid and rifampicin, while extensively drug-resistant tuberculosis (XDR-TB) shows additional resistance to fluoroquinolones and second-line injectable drugs, leading to prolonged treatment and poor outcomes**.** The increasing prevalence of these antibiotic-resistant pathogens highlights the urgent need for improved surveillance, rational antibiotic use, and the development of novel antimicrobial agents.

4. Factors Contributing to Antibiotic Resistance

Antibiotic resistance is a multifactorial problem driven by human behavior, healthcare practices, agricultural activities, and microbial evolution. The interaction of these factors accelerates the emergence and spread of resistant microorganisms across communities and healthcare settings.

Inappropriate and Excessive Use of Antibiotics

One of the primary drivers of antibiotic resistance is the irrational use of antibiotics in clinical practice. This includes over prescription, use of broad-spectrum antibiotics when narrow-spectrum agents would suffice, incorrect dosing, and failure to complete prescribed treatment courses. Additionally, antibiotics are frequently used to treat viral infections, where they provide no therapeutic benefit, further promoting resistance.

Self-Medication and Over-the-Counter Availability

In many regions, particularly in developing countries, antibiotics are readily available without prescription. Self-medication, reuse of leftover antibiotics, and sharing medications among individuals contribute significantly to subtherapeutic dosing and selection of resistant bacterial strains.

Use of Antibiotics in Agriculture and Animal Husbandry

The extensive use of antibiotics as growth promoters and for disease prevention in livestock and poultry plays a crucial role in the development of resistant bacteria. These resistant organisms can be transmitted to humans through the food chain, direct animal contact, or environmental contamination, emphasizing the importance of a One Health approach.

Poor Infection Control and Sanitation

Inadequate infection prevention and control measures, including poor hand hygiene, insufficient sterilization of medical equipment, overcrowding in hospitals, and lack of clean water and sanitation, facilitate the spread of resistant pathogens, particularly in healthcare settings.

Lack of Rapid Diagnostic Tools

The absence of rapid and accurate diagnostic methods often leads to empirical and inappropriate antibiotic prescribing. Delayed identification of causative pathogens and their susceptibility profiles results in unnecessary exposure to broad-spectrum antibiotics.

Limited Development of New Antibiotics

The slowdown in antibiotic research and development due to high costs, regulatory challenges, and low commercial returns has created a gap between emerging resistance and available treatment options. This has intensified reliance on existing antibiotics, further accelerating resistance.

5. Clinical and Economic Impact

Antibiotic-resistant infections are associated with increased treatment failure, prolonged hospital stays, and higher mortality rates. The economic burden includes increased healthcare costs, loss of productivity, and the need for expensive second-line therapies. Developing countries are disproportionately affected due to limited access to advanced diagnostics and effective antibiotics.

Clinical Impact

Antibiotic-resistant infections are associated with increased morbidity and mortality due to delayed effective treatment and limited therapeutic options. Patients infected with resistant organisms often experience prolonged illness, higher rates of treatment failure, and an increased risk of complications. In severe cases, such as sepsis or pneumonia caused by multidrug-resistant pathogens, mortality rates are significantly higher compared to infections caused by susceptible strains. Resistant infections frequently result in longer hospital stays and increased need for intensive care, invasive procedures, and isolation measures. The use of second-line or last-resort antibiotics, such as colistin or linezolid, is often required; these agents may be less effective, more toxic, and associated with serious adverse effects. Vulnerable populations, including elderly patients, neonates, immunocompromised individuals, and patients with chronic diseases, are particularly at risk.

Economic Impact

The economic burden of antibiotic resistance is substantial and multifaceted. Increased healthcare costs arise from prolonged hospitalization, additional diagnostic tests, and the use of expensive alternative antimicrobial agents. Hospitals face higher operational costs due to infection control measures, isolation facilities, and extended patient care. Beyond direct healthcare expenses, antibiotic resistance leads to significant indirect costs, including loss of productivity due to prolonged illness or premature death. At a societal level, resistant infections place strain on healthcare infrastructure and contribute to reduced workforce efficiency. In low- and middle-income countries, these economic impacts are further exacerbated by limited healthcare resources and access to effective treatments. Overall, antibiotic resistance threatens not only individual patient outcomes but also the sustainability of healthcare systems and economic development, highlighting the urgent need for effective prevention and control strategies.

6. Strategies for Prevention and Control

Effective prevention and control of antibiotic resistance require a comprehensive and coordinated approach involving healthcare professionals, policymakers, researchers, and the general public. Multiple strategies must be implemented simultaneously to reduce the emergence and spread of resistant pathogens.

Antimicrobial Stewardship Programs

Antimicrobial stewardship programs (ASPs) are essential for promoting the rational use of antibiotics in healthcare settings. These programs focus on optimizing antibiotic selection, dosing, duration, and route of administration to achieve the best clinical outcomes while minimizing resistance development. Stewardship interventions include prescribing

guidelines, audit and feedback systems, and education of healthcare professionals.

Infection Prevention and Control Measures

Strict infection prevention and control practices play a crucial role in limiting the transmission of resistant microorganisms. These measures include proper hand hygiene, use of personal protective equipment, environmental cleaning, sterilization of medical instruments, and isolation of infected or colonized patients. Vaccination programs also help reduce the incidence of bacterial infections and subsequent antibiotic use.

Surveillance and Monitoring

Continuous surveillance of antibiotic resistance patterns is vital for early detection of emerging resistant strains and for guiding empirical therapy. National and global surveillance networks enable data sharing and support evidence-based policy decisions. Routine antimicrobial susceptibility testing in clinical laboratories is a key component of surveillance efforts.

Public Education and Awareness

Raising awareness among patients and the general public about the appropriate use of antibiotics is essential to prevent misuse. Educational campaigns should emphasize the importance of completing prescribed antibiotic courses, avoiding self-medication, and understanding that antibiotics are ineffective against viral infections.

Regulation of Antibiotic Use in Agriculture

Implementing strict regulations on the use of antibiotics in agriculture and animal husbandry is critical to reducing resistance transmission through the food chain. Banning the use of antibiotics as growth promoters and promoting alternatives such as improved hygiene, vaccination, and probiotics can significantly reduce antibiotic dependence in livestock.

Research and Development of New Therapeutics

Investment in research and development is necessary to overcome the growing resistance crisis. This includes the discovery of novel antibiotics, development of β-lactamase inhibitors, efflux pump inhibitors, and alternative therapies such as bacteriophage therapy, antimicrobial peptides, and immunomodulatory approaches. Advances in rapid diagnostic technologies can also support targeted therapy.

7. Future Perspectives

Global surveillance systems, international collaboration, and the integration of artificial intelligence in antibiotic discovery are expected to enhance resistance monitoring and drug development. Strengthening policy frameworks and incentivizing pharmaceutical research are crucial for sustaining progress against antibiotic resistance. Addressing antibiotic resistance in the coming decades will require innovative scientific approaches, strengthened global cooperation, and sustained policy interventions. As resistance continues to outpace the development of new antibiotics, future strategies must focus on both preserving existing antimicrobial agents and advancing alternative therapeutic options. The integration of **advanced molecular diagnostics** and **rapid point-of-care testing** is expected to significantly improve early pathogen identification and antimicrobial susceptibility profiling. These technologies will enable clinicians to initiate targeted therapy, reduce empirical broad-spectrum antibiotic use, and limit unnecessary exposure to antimicrobials.

Artificial intelligence and machine learning are increasingly being applied to antibiotic discovery, drug repurposing, and resistance prediction. These technologies can accelerate the identification of novel antimicrobial compounds, optimize drug combinations, and forecast resistance trends, thereby supporting proactive intervention strategies. The development of **non-traditional therapies** offers promising alternatives to conventional antibiotics. Approaches such as bacteriophage therapy, antimicrobial peptides, CRISPR-Cas–based antimicrobials, and microbiome-modulating strategies aim to selectively target pathogens while minimizing disruption to beneficial microbiota. Additionally, host-directed therapies and immunomodulators may enhance immune responses and reduce reliance on antibiotics. From a public

health perspective, strengthening **global surveillance systems** and adopting a **One Health approach** that integrates human, animal, and environmental health will be critical. International collaboration, data sharing, and harmonized regulatory frameworks can support coordinated responses to emerging resistance threats. Policy reforms that incentivize antibiotic research and development, alongside sustainable funding models and public–private partnerships, are essential to revitalize the antibiotic pipeline. Continued education, stewardship efforts, and investment in research infrastructure will ultimately determine the success of future efforts to control antibiotic resistance.

CONCLUSION

Antibiotic resistance poses a serious threat to global health and undermines the achievements of modern medicine. Addressing this challenge requires a multifaceted approach involving rational antibiotic use, effective infection control, continuous surveillance, and innovation in antimicrobial research. Coordinated efforts at local, national, and global levels are essential to curb the spread of antibiotic resistance. Antibiotic resistance represents a critical and escalating threat to global public health, undermining decades of progress in the treatment of infectious diseases. The emergence of multidrug-resistant pathogens has significantly reduced the effectiveness of commonly used antibiotics, leading to increased morbidity, mortality, and economic burden worldwide. Resistance arises through diverse mechanisms, including enzymatic inactivation, target site modification, reduced drug permeability, and efflux pump overexpression, often acting synergistically to confer high-level resistance. Multiple factors, such as inappropriate antibiotic use, self-medication, agricultural practices, poor infection control, and limited development of new antimicrobials, contribute to the rapid spread of resistance. Addressing this challenge requires a multifaceted approach that integrates antimicrobial stewardship, robust infection prevention measures, continuous surveillance, public education, and strict regulatory policies. Future efforts must focus on innovation in antibiotic discovery, rapid diagnostics, and alternative therapeutic strategies, supported by global collaboration and a One Health framework. Sustained commitment from healthcare professionals, policymakers, researchers, and society is essential to preserve the effectiveness of existing antibiotics and ensure successful management of bacterial infections for future generations.

REFERENCES

1. World Health Organization. Antimicrobial resistance. Geneva: WHO; 2023.
2. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
3. Ventola CL. The antibiotic resistance crisis: part 1—causes and threats. P T. 2015;40(4):277–283.
4. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.
5. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318.
6. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):1–37.
7. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
8. Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8): a025247.
9. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20–51.
10. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem. 2009; 78:119–146.
11. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list. Lancet Infect Dis. 2018;18(3):318–327.
12. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens. J Infect Dis. 2008;197(8):1079–1081.
13. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187.

14. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Resistance; 2016.
15. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014; 6:25–64.
16. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(12 Suppl): S122–S129.
17. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: a guide for clinicians. J Anaesthesiol Clin Pharmacol. 2017;33(3):300–305.
18. Ventola CL. The antibiotic resistance crisis: part 2—management strategies and new agents. P T. 2015;40(5):344–352.
19. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299–302.
20. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta: CDC; 2019.
21. World Health Organization. Antimicrobial resistance. WHO; 2023.
22. Ventola CL. The antibiotic resistance crisis. P&T. 2015;40(4):277–283.
23. Laxminarayan R, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.
24. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
25. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318.

Cite: Sanjana Ostwal*, Padma Pawar, Minakshi Londhe, Ashwini Shewale, Shital Boraste, Antibiotic Resistance: A Global Public Health Challenge – A Review, Int. J. Med. Pharm. Sci., 2026, 2 (4), 51-58. https://doi.org/10.5281/zenodo.19473566